| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2272 |
| Trial ID | NCT04196491 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel |
| Location approved | US, Canada, EU, UK, Japan, Israel, Switzerland |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) |
| Year | 2019 |
| Country | United States |
| Company sponsor | Celgene |
| Other ID(s) | BB2121-MM-004|U1111-1243-5088 |
| Cohort 1 | |||||||||||||
|
|||||||||||||